Criminals are targeting pharmacies and stealing weight-loss medication in a country with ... (The Brazilian market still pales in comparison to the United States, where sales totaled $30.3 billion ...

The rise of weight-loss drugs like Ozempic and Wegovy have upended ... $64.7 million — a shadow of its $6.7 billion peak. By comparison, Ozempic-maker Novo Nordisk is valued at $2.6 trillion.

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...

Being about 80 to 100 pounds over the reference body weight for your height could put you in the category of morbidly obese on the BMI chart. A high BMI might ... to begin morbid obesity treatment.

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Dr. Alexandra Sowa, an obesity medicine specialist and author of the new book “The Ozempic Revolution” shares the pros and cons of using GLP-1 medications for weight loss. The FDA has expanded ...

Popular drugs for diabetes and weight loss could have an unexpected side effect. Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

The landscape of weight ... medications. Regular eye examinations become essential for detecting any early changes in vision. Careful tracking of blood sugar levels and the pace of weight loss ...